Here’s a bold statement: What if stopping blood thinners after a successful atrial fibrillation (AF) ablation could be safe for certain patients? This idea is shaking up the medical world, and the OCEAN trial is at the heart of the debate. But here’s where it gets controversial—while the trial suggests low-risk patients might not need oral anticoagulants (DOACs) post-ablation, experts warn this doesn’t apply to everyone. Let’s dive in.
The Core Findings: Presented at the American Heart Association 2025 Scientific Sessions, the OCEAN trial revealed no significant difference in stroke risk or other adverse outcomes between patients treated with aspirin and those on the direct oral anticoagulant rivaroxaban (Xarelto) after successful AF ablation. Over 36 months, rates of stroke, systemic embolism, and small cerebral infarctions detected by MRI were strikingly similar in both groups. And this is the part most people miss—lead investigator Dr. Atul Verma suggests patients with a CHA2DS2-VASc score of 1, 2, or even 3 might safely discontinue DOACs, though he cautions this doesn’t apply to those with recent strokes.
The Debate Deepens: Current guidelines recommend long-term anticoagulation based on stroke risk, but the OCEAN and ALONE-AF trials challenge this. Dr. Verma admits, ‘Every single patient asks, can I get off my blood thinner?’ This common question fueled the trial, but the answer isn’t black and white. Electrophysiologist Dr. Oussama Wazni agrees that while stopping DOACs seems reasonable for low-risk patients in normal sinus rhythm, real-world decisions remain tricky. ‘We’ve all seen patients with a CHA2DS2-VASc score of 0 who still had a stroke,’ he warns, emphasizing the need for careful patient conversations.
Controversial Counterpoint: Dr. Christine Albert highlights that anticoagulation is often continued due to concerns about silent AF and stroke risk. Yet, OCEAN provides crucial risk-benefit data, suggesting patients a year out from successful ablation with low-to-moderate stroke risk might not need DOACs. But here’s the kicker—the trial used aspirin as a comparator, which some now view as ineffective in reducing stroke risk, raising questions about its role in the study.
What’s Next?: For electrophysiologist Dr. Michael Ghannam, the trial answers a pressing clinical question as AF prevalence rises. While he wouldn’t broadly discontinue anticoagulants, especially in high-risk patients, he sees value in discussing DOAC cessation for low-risk individuals, particularly those at high bleeding risk. Dr. Wazni suggests apixaban as a safer alternative for those hesitant to stop anticoagulation altogether.
Final Thought-Provoking Question: Should we rethink long-term anticoagulation for low-risk AF patients post-ablation, or is the risk of stroke still too great to take the chance? Share your thoughts in the comments—this debate is far from over.
